

**NEWS RELEASE  
FOR IMMEDIATE RELEASE**

**Company Contact:**  
Stan Fronczkowski  
Chief Financial Officer  
(302) 456-6789  
[www.sdix.com](http://www.sdix.com)

**Investor Contact:**  
Brian Korb  
The Trout Group  
(646) 378-2923  
[bkorb@troutgroup.com](mailto:bkorb@troutgroup.com)

**Strategic Diagnostics Appoints Deborah Day Barbara as  
Vice President of Business Development**

**NEWARK, Del., October 21, 2008 – Strategic Diagnostics Inc. (Nasdaq – SDIX)** – today announced that Deborah Day Barbara has joined the Company as its Vice President of Business Development, effective October 13, 2008. Ms. Barbara was most recently Vice President of Business Development and Licensing for Ore Pharmaceuticals in Gaithersburg, Maryland. Ms. Barbara has over 20 years of experience in the areas of business development, licensing, intellectual property management, strategic planning and technology development. While working at Ore Pharmaceuticals, Ms. Barbara led drug evaluation partnership negotiations with several prominent pharmaceutical companies, resulting in valuable business relationships and a pipeline of clinical stage drug candidates. Immediately prior to joining Ore Pharmaceuticals, Ms. Barbara was Senior Director of Business and Technology Development for Johns Hopkins University, and was responsible for developing numerous licensing and research agreements. She also spent 11 years at Amersham Life Sciences in a variety of sales leadership positions.

“We welcome Deborah Day Barbara to SDI’s executive team,” commented Fran DiNuzzo, the Company’s President and CEO. “Deborah brings a wealth of experience in the Life Science market. Her expertise in business development has resulted in a strong record of bringing important partnerships together. She will continue to help SDI move in the right strategic direction to better leverage our technology platforms. As our technologies continue to gain acceptance and recognition, we are increasingly looking at opportunities to collaborate with pharmaceutical, biotechnology and diagnostic industry leaders. Deborah will play an important role in ensuring that the Company has secured the appropriate balance of value creation and revenue based partnerships necessary to achieve sustained growth.”

“SDI is a company with exciting new proprietary technology and proven technical expertise,” added Ms. Barbara. “I look forward to working with Fran and the SDI team to expand the commercial paths for this technology through development of key collaborations and partnerships. We expect these business development activities to advance the Company’s presence and expand market share in targeted markets.”

**About Strategic Diagnostics Inc.**

Strategic Diagnostics Inc. is a leading provider of antibody technology to the Life Science market place. Additionally the company provides biotechnology-based detection solutions for a broad range of food, water, agricultural, and environmental applications. By applying its core competencies of antibody and assay development, the Company produces unique, sophisticated reagents, reagent systems, antibody design services and bio-detection solutions to customer needs. Customers benefit

from the enablement of their research into critical health care challenges of disease understanding, therapeutic development and diagnostic discovery. Industrial customers benefit with quantifiable “return on investment” by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in antibody design, immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company’s established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in proteomics research and discovery.

*This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project” “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.*